BioSpace News Archive

Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce that its recent oral nicotine absorption study NIC-A21-1 revealed that DehydraTECHTM-nicotine delivered via the oral pouch product format required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, announces that C. Lowry Barnes, MD, Chair of Orthopaedics at the University of Arkansas for Medical Sciences Health, has officially joined the company’s leadership team as Medical Director.

Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients.

Gator Bio, Inc. announced the launch of the Gator™ SMAP probe and Gator™ mFC probe for GatorPrime and GatorPlus biolayer interferometry (BLI) systems today.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021.

Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas

AiPharma Global Holdings LLC (“AiPharma”) a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases today announced it has entered a binding agreement to sell all of its assets through the sale of one of its wholly owned group subsidaries, to Aditxt Inc. (Nasdaq: ADTX).

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced the closing of its previously announced registered direct offering of 4,307,693 shares of the Company’s common stock, at a purchase price of $3.25 per share.

MedSource Labs announced that the VeroTrue™ Conventional IV Catheter, long trusted by healthcare providers outside of the U.S., is now available domestically.